The decline in Novavax's stock price is directly linked to Moderna's revised expectations, which highlight broader market challenges that could similarly affect Novavax. Concerns about low EU sales, potential revenue deferrals, and increased competition in the U.S. respiratory vaccine market are likely to weigh on investor sentiment and impact Novavax's short-term stock performance.